Hint mode is switched on Switch off
For swift navigation between sections

Oyster Point Pharma

PDF download

Choose all Reset all
Download Cancel
Organization name
Oyster Point Pharma, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Oyster Point Pharma, Inc. operates as a biopharmaceutical company. The Company discovers and develops novel therapies to treat ocular surface diseases. Oyster Point Pharma serves patients in the United States.

Awards

News

03/01/2023 Oyster Point Pharma: Termination Of A Material Definitive Agreement. The Original Form 8k Stated That The Aggregate Payoff Amount For The Credit Agreement And Guaranty, Dated As Of August 5, 2021, By And Among Oyster Point, The Subsidiary Guarantors Party Thereto, The Lenders Party Thereto And Orbimed Royalty & Credit Opportunities Iii, Lp (as Amended From Time To Time, The Orbimed Credit Agreement ) Was Approximately $298.8 Million. This Amendment Corrects Such Mistake By Amending And Restating Item 1.02 Of The Original Form 8k To Clarify That The Aggregate Payoff Amount For The Orbimed Credit Agreement Was Approximately $112.2 Million. Except For This Typographical Mistake Described Above, This Amendment Does Not Modify Or Update Any Of The Other Information Set Forth In The Original Form 8k, Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continuing Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
03/01/2023 Oyster Point Pharma: Termination Of A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continuing Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
10/11/2022 Oyster Point Pharma: Results Of Operations And Financial Condition, Financial Statements And Exhibits
07/11/2022 Oyster Point Pharma: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
07/11/2022 Oyster Point Pharma: Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2022
I q eng
II q eng
III q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001720725
Registration is required to get access.